Letters

Hypocalcaemia after intravenous bisphosphonate

BMJ 2004; 328 doi: https://doi.org/10.1136/bmj.328.7453.1439-b (Published 10 June 2004) Cite this as: BMJ 2004;328:1439

Adjuvant bisphosphonate is not currently accepted practice

  1. Carlo Palmieri, specialist registrar in medical oncology,
  2. Tony Dhillon, specialist registrar in medical oncology,
  3. Charles Coombes, professor of cancer medicine,
  4. David Vigushin, senior lecturer in cancer medicine
  1. Department of Medical Oncology, Charing Cross Hospital, London W6 8RF
  2. Department of Medical Oncology, Charing Cross Hospital, London W6 8RF
  3. Department of Medical Oncology, Charing Cross Hospital, London W6 8RF

    EDITOR—Peter et al say that bisphosphonates can be used as prophylaxis against metastatic bone cancer1; this statement is incorrect. Although nitrogen containing bisphosphonates such as zoledronic acid can inhibit specific enzymes in the mevalonate pathway and thus affect tumour growth by inducing apoptosis,2 their use as adjuvant …

    View Full Text

    Sign in

    Log in through your institution

    Free trial

    Register for a free trial to thebmj.com to receive unlimited access to all content on thebmj.com for 14 days.
    Sign up for a free trial

    Subscribe